Indaptus Therapeutics
INDP | NASDAQ
$3.45
+$0.28 (+8.83%)
At close: Nov 16, 2026, 4:00 PM ET
$3.45
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:34 PM ET
Indaptus Therapeutics Company Profile
Company profile explainedCompany Profile
Indaptus Therapeutics, Inc. is a biotechnology company operating in the pre-clinical phase, dedicated to developing a range of immunotherapeutic products for the treatment of both cancer and viral infections. The firm's lead investigational compound, Decoy20, is currently progressing through Phase I clinical trials. This candidate is being evaluated for its capacity to elicit lasting therapeutic responses, either as a standalone agent or in combination with other treatments, for various conditions including lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as infections caused by the hepatitis B virus and human immunodeficiency virus. Initially incorporated in 2021 under the name Intec Parent, Inc., the company officially rebranded to Indaptus Therapeutics, Inc. in August of the same year. Its corporate headquarters are situated in New York, New York.
Key Executives
| Name | Position |
|---|---|
| Junyi Dai | CEO & Chairman |
| Yu Ding | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 22, 2026 | SC 13D/A | [Amend] Filing |
| Oct 22, 2026 | SC 13D/A | [Amend] Filing |
| Oct 22, 2026 | SC 13D/A | [Amend] Filing |
| Oct 21, 2026 | SC 13D/A | [Amend] Filing |
| Oct 20, 2026 | 8-K | Current Report |
| Oct 05, 2026 | S-8 | Filing |
| Sep 30, 2026 | 8-K | Current Report |
| Sep 10, 2026 | 8-K | Current Report |
| Sep 08, 2026 | 8-K/A | [Amend] Current Report |
| Sep 04, 2026 | 8-K | Current Report |
Indaptus Therapeutics
| Country | United States |
| IPO Date | Aug 4, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5 |
| CEO | Junyi Dai |
Contact Details
3 Columbus Circle New York City,
New York 10019 United States
Stock Details
| Ticker Symbol | INDP |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001857044 |
| CUSIP Number | 45339J204 |
| ISIN Number | US45339J2042 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove INDP